---
document_datetime: 2025-11-06 14:32:01
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/quadramet-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: quadramet-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.1927488
conversion_datetime: 2025-12-24 14:46:13.075306
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Quadramet

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/2682/ 202402   | Periodic Safety Update EU Single assessment - samarium (153sm) lexidronam                                                                                 | 03/10/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| IA/0028              | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph | 29/09/2021                          | n/a                                         |                                  |                                   |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | of the Ph. Eur. or national pharmacopoeia of a Member State                                                                                                                                                  |            |     |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0027            | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                   | 29/09/2021 | n/a |                                   |
| IB/0026            | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 20/12/2019 | n/a |                                   |
| IB/0024            | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                       | 20/12/2019 | n/a |                                   |
| IA/0025            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                | 22/10/2019 | n/a |                                   |
| PSUSA/2682/ 201902 | Periodic Safety Update EU Single assessment - samarium (153sm) lexidronam                                                                                                                                    | 05/09/2019 | n/a | PRAC Recommendation - maintenance |
| IB/0022            | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                               | 04/05/2018 | n/a |                                   |
| PSUSA/2682/ 201602 | Periodic Safety Update EU Single assessment - samarium (153sm) lexidronam                                                                                                                                    | 02/09/2016 | n/a | PRAC Recommendation - maintenance |
| IG/0557            | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the                                                            | 21/05/2015 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | PSMF location                                                                                                                                                                                                                                                                                                         |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0019 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                        | 04/05/2015 | 02/05/2016 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0018   | To widen the specification limits for samarium content B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP | 24/05/2012 | 14/06/2012 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IG/0015   | C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD                                                            | 06/08/2010 | n/a        | Annex II    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0016   | Update to SmPC section 4.8 and PL following a signal detection assessment. Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                           | 26/06/2008 | 23/07/2008 | SmPC and PL | Following the assessment of a signal detection, the CHMP requested that the product information for Quadramet should be amended to include post-marketing reports of thrombocytopenia in section 4.8. The PL has been amended accordingly. These changes were requested further to a review performed following the detection of a signal where post- marketing cases of thrombocytopenia including isolated reports of intracranial haemorrhage, and cases in which the |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                  |            |            |                                  | outcome was fatal have been reported.                                                                                                                                                                                                                               |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0015  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 11/04/2008 | n/a        | PL                               |                                                                                                                                                                                                                                                                     |
| R/0014  | Renewal of the marketing authorisation.                                                          | 18/10/2007 | 12/12/2007 | SmPC, Labelling and PL           | Based upon data that have become available since the granting of the marketing authorisation, the CHMP considers that the benefit-risk balance of Quadramet remains positive ad thus recommends the renewal of the Marketing Authorisation with unlimited validity. |
| N/0013  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 13/04/2007 | n/a        | PL                               |                                                                                                                                                                                                                                                                     |
| N/0012  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 22/09/2006 | n/a        | PL                               |                                                                                                                                                                                                                                                                     |
| IA/0011 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                 | 23/06/2004 | n/a        |                                  |                                                                                                                                                                                                                                                                     |
| N/0010  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 25/05/2004 | n/a        | PL                               |                                                                                                                                                                                                                                                                     |
| R/0009  | Renewal of the marketing authorisation.                                                          | 18/12/2002 | 17/03/2003 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                     |
| N/0008  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 07/06/2002 | 27/06/2002 | PL                               |                                                                                                                                                                                                                                                                     |
| N/0007  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 15/03/2002 | 19/04/2002 | PL                               |                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| N/0006   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 23/10/2001   | 17/12/2001   | PL   |
|----------|----------------------------------------------------------------------------------------------------|--------------|--------------|------|
| N/0005   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 23/10/2001   | n/a          | PL   |
| N/0004   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 16/08/2000   | 09/10/2000   | PL   |
| I/0003   | 15_Minor changes in manufacture of the medicinal product                                           | 23/12/1998   | n/a          |      |
| I/0002   | 15_Minor changes in manufacture of the medicinal product                                           | 23/12/1998   | n/a          |      |
| I/0001   | 12_Minor change of manufacturing process of the active substance                                   | 23/12/1998   | n/a          |      |